Neuropharm's shares start trading on the AIM
The Ordinary Shares from Neuropharm's recent L20.0 million ($38.5 million) placing have been admitted to trading on the Alternative Investments Market of the London Stock Exchange. The UK-based speciality pharmaceutical group, which is focused on disorders of the central nervous system, said that dealings commenced on the AIM at 8.00am on March 7 in the ordinary shares issued to non-VCT investors, under the ticker symbol NPH.
Neuropharm's pipeline includes a US orphan drug designation in respect of the use of fluoxetine for the treatment of Autistic Spectrum Disorder (NPL-2008) and, subject to obtaining regulatory approval, is preparing for a proposed launch in the USA of an orally-dissolving tablet formulation during the fourth quarter of 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze